CO2020006181A2 - Detergentes compatibles con el medio ambiente para la inactivación de virus envueltos en lípidos - Google Patents

Detergentes compatibles con el medio ambiente para la inactivación de virus envueltos en lípidos

Info

Publication number
CO2020006181A2
CO2020006181A2 CONC2020/0006181A CO2020006181A CO2020006181A2 CO 2020006181 A2 CO2020006181 A2 CO 2020006181A2 CO 2020006181 A CO2020006181 A CO 2020006181A CO 2020006181 A2 CO2020006181 A2 CO 2020006181A2
Authority
CO
Colombia
Prior art keywords
lipid
inactivation
environmentally friendly
enveloped viruses
detergents
Prior art date
Application number
CONC2020/0006181A
Other languages
English (en)
Inventor
Thomas Kreil
Jean-Baptiste Farcet
Johanna Kindermann
Björn Tille
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of CO2020006181A2 publication Critical patent/CO2020006181A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2612—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aromatic or arylaliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • C11D1/66—Non-ionic compounds
    • C11D1/72—Ethers of polyoxyalkylene glycols
    • C11D1/721—End blocked ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
    • C08G59/14—Polycondensates modified by chemical after-treatment
    • C08G59/1433—Polycondensates modified by chemical after-treatment with organic low-molecular-weight compounds
    • C08G59/1438—Polycondensates modified by chemical after-treatment with organic low-molecular-weight compounds containing oxygen
    • C08G59/1444—Monoalcohols
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3344—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur
    • C08G65/3346—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur having sulfur bound to carbon and oxygen
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/36—Organic compounds containing phosphorus
    • C11D3/362—Phosphates or phosphites
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/37—Polymers
    • C11D3/3703—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3707—Polyethers, e.g. polyalkyleneoxides
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/43—Solvents
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361—Methods of inactivation or attenuation
    • C12N2770/24363—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polyethers (AREA)
  • Detergent Compositions (AREA)

Abstract

La presente invención se refiere a métodos para inactivar un virus envuelto en lípidos usando detergentes compatibles con el medio ambiente, y a métodos para preparar un fármaco biofarmacéutico utilizando detergentes compatibles con el medio ambiente. La invención también proporciona detergentes compatibles con el medio ambiente.
CONC2020/0006181A 2017-10-30 2020-05-20 Detergentes compatibles con el medio ambiente para la inactivación de virus envueltos en lípidos CO2020006181A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762578648P 2017-10-30 2017-10-30
US201862687023P 2018-06-19 2018-06-19
PCT/EP2018/079721 WO2019086463A1 (en) 2017-10-30 2018-10-30 Environmentally compatible detergents for inactivation of lipid-enveloped viruses

Publications (1)

Publication Number Publication Date
CO2020006181A2 true CO2020006181A2 (es) 2020-10-30

Family

ID=64083092

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0006181A CO2020006181A2 (es) 2017-10-30 2020-05-20 Detergentes compatibles con el medio ambiente para la inactivación de virus envueltos en lípidos

Country Status (12)

Country Link
US (1) US12258540B2 (es)
EP (1) EP3704178B1 (es)
JP (1) JP7432506B2 (es)
KR (1) KR102651043B1 (es)
CN (1) CN111511800B (es)
AU (1) AU2018357917B2 (es)
CA (1) CA3080656A1 (es)
CO (1) CO2020006181A2 (es)
ES (1) ES2991988T3 (es)
MX (1) MX2020004151A (es)
SG (1) SG11202003793WA (es)
WO (1) WO2019086463A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
TW202220949A (zh) * 2020-08-05 2022-06-01 日商武田藥品工業股份有限公司 製備及純化與環境相容的清潔劑之方法
WO2024115344A1 (en) 2022-11-29 2024-06-06 Merck Patent Gmbh Method for inactivating enveloped viruses

Family Cites Families (381)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1970578A (en) 1930-11-29 1934-08-21 Ig Farbenindustrie Ag Assistants for the textile and related industries
GB1041554A (en) 1961-10-11 1966-09-07 W J Bush & Company Ltd Improvements in or relating to the dyeing of fibres
DE2154996A1 (de) 1971-11-05 1973-05-10 Bayer Ag Anthrachinonfarbstoffe
JPS527372B2 (es) 1972-07-14 1977-03-02
US4020183A (en) 1974-12-03 1977-04-26 Ortho Pharmaceutical Corporation Nonionic surface active anti-herpes simplex viral agents
SE437329B (sv) 1975-03-14 1985-02-25 Community Blood Council Sett att ur blodserum framstella vaccin mot virushepatit
JPS5265591A (en) 1975-11-26 1977-05-31 Mitsui Petrochem Ind Ltd Purification of polyolefins
DE2605469C3 (de) 1976-02-12 1980-04-10 Behringwerke Ag, 3550 Marburg Verfahren zur Gewinnung eines Spaltprodukts des Tollwut-Virus und dieses enthaltender Impfstoff
US4113712A (en) 1976-03-08 1978-09-12 The Green Cross Corporation HBsAG Particle composed of single polypeptide subunits and the preparation procedure
DE2615161A1 (de) 1976-04-07 1977-10-27 Thiemann Chem Pharm Fab Omega-aminoalkoxy-alkane, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FI66020C (fi) 1977-09-19 1984-08-10 Merck & Co Inc Foerfarande foer framstaellning av antigeniska immunogeniska subunits av hsv-1 och hsv-2
US4374127A (en) 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
DE2750045A1 (de) 1977-11-09 1979-05-10 Behringwerke Ag Verfahren zur entfernung von detergentien aus virusantigensuspensionen
ZA792485B (en) 1978-06-07 1980-06-25 New York Blood Center Inc Vaccine for active immunization containing hepatitis b surface and/or e-antigens
DE2847959A1 (de) 1978-11-04 1980-05-14 Behringwerke Ag Verfahren zur isolierung von virusantigenen mittels polyaethylenglykol aus loesungen, die nicht-ionische detergentien enthalten
JPS5940174B2 (ja) 1978-11-16 1984-09-28 財団法人相模中央化学研究所 液体シンチレ−タ−溶液
DK276380A (da) 1979-07-09 1981-01-10 Univ Iowa State Res Found Inc Fremgangsmaade til fremstilling af en vaccine mod infektioes kvaeg-rhinotracheitis
US4452734A (en) 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
FR2475572A1 (fr) 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
DE3005495C2 (de) 1980-02-14 1983-03-31 Institut Pasteur, 75724 Paris Herstellung von Fragmenten von Viren mit Lipidhülle und sie enthaltende Arzneimittelzubereitungen
DE3014189A1 (de) 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
ZW9881A1 (en) 1980-06-02 1981-12-23 Hoffmann La Roche Substituted phenoxyaminopropanol derivatives
DE3173208D1 (en) 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
AR228580A1 (es) 1980-11-25 1983-03-30 Torre Jose Leonardo Procedimiento para inactivar el virus de la fiebre aftosa
JPS5795917A (en) 1980-12-04 1982-06-15 Takeda Chem Ind Ltd Preparation of inactivated sendai virus vaccine
US4327182A (en) 1981-01-22 1982-04-27 Connaught Laboratories Incorporated Purification of influenza sub-unit vaccine
US4975217A (en) 1981-07-20 1990-12-04 Kimberly-Clark Corporation Virucidal composition, the method of use and the product therefor
US4481189A (en) 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4645666A (en) 1982-06-08 1987-02-24 The Regents Of The University Of California Vaccine for bluetongue disease employing platinum compounds
US4511556A (en) 1982-06-10 1985-04-16 The United States Of America As Represented By The Department Of Health And Human Services Inactivation of a lipid virus
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS6041770A (ja) 1983-08-17 1985-03-05 Hitachi Ltd 燃料電池装置
JPS6051120A (ja) 1983-08-31 1985-03-22 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニットワクチン
GB8405521D0 (en) 1984-03-02 1984-04-04 Abm Chemicals Ltd End-blocked nonionic surfactants
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4613501A (en) 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
US4673733A (en) 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT385203B (de) 1985-04-26 1988-03-10 Immuno Ag Verfahren zur herstellung einer fruehsommermeningoenzephalitis-virus (fsme-virus)-vakzine
US4649192A (en) 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
JPS63501121A (ja) 1985-08-15 1988-04-28 アムジエン 酵母細胞からｂ型肝炎表面抗原を抽出するための細胞溶解法および緩衝液
US5426029A (en) 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US4789545A (en) 1986-03-31 1988-12-06 New York Blood Center, Inc. Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
DE3704550A1 (de) 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US4943624A (en) 1988-10-28 1990-07-24 Lehigh University Supramolecular surfactants: amphiphilic polymers designed to disrupt lipid membranes
JPH02184842A (ja) 1989-01-11 1990-07-19 Konica Corp 帯電防止性及び塗布性が改良されたハロゲン化銀写真感光材料
ES2057191T5 (es) 1989-01-13 2003-05-01 Mitsubishi Pharma Corp Metodo de produccion para una composicion que contiene proteinas.
HK1003981A1 (en) 1989-01-27 1998-11-13 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
JPH02272068A (ja) 1989-04-13 1990-11-06 Mitsubishi Monsanto Chem Co 合わせガラス用着色ポリビニルブチラール中間膜及びその着色剤組成物
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
AU636907B2 (en) 1989-08-29 1993-05-13 Commonwealth Scientific And Industrial Research Organisation Bovine ephemeral fever and antigens and vaccines derived therefrom
GB8919819D0 (en) 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
JPH03168737A (ja) 1989-11-29 1991-07-22 Konica Corp 高コントラストな画像と高品質な網点が得られるハロゲン化銀写真感光材料
US5418130A (en) 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US6251644B1 (en) 1990-04-16 2001-06-26 Baxter International, Inc. Method for inactivating non-enveloped viral contaminants with a photosensitizer by increasing viral permeability to the photosensitizer
US5712086A (en) 1990-05-15 1998-01-27 New York Blood Center, Inc. Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions
US5232844A (en) 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5981163A (en) 1990-05-15 1999-11-09 New York Blood Center, Inc. Process for the sterilization of biological compositions using irradiation and quenchers of type I and type II photodynamic reactions
DE4033446A1 (de) 1990-10-20 1992-04-23 Bayer Ag Impfstoffe gegen equine herpesviren und ihre herstellung
US5314917A (en) 1991-03-22 1994-05-24 E. B. Michaels Research Associates, Inc. Method for inactivating enveloped viruses and sperm
WO1994028120A1 (en) 1991-05-10 1994-12-08 New York Blood Center, Inc. Process for the sterilization of biological compositions and the product produced thereby
IT1248075B (it) 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
DE4125625C2 (de) 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
CA2096650A1 (en) 1991-09-18 1993-03-21 Keith E. Langley Hepatitis b vaccine formulation incorporating a bile acid salt
FR2686221B1 (fr) 1992-01-22 2000-02-25 Hutchinson Compositions a base d'antiseptiques et leurs applications.
WO1993017723A1 (en) 1992-03-02 1993-09-16 Simmons Paul L Biodegradable surface disinfectant
AU667530B2 (en) 1992-05-28 1996-03-28 New York Blood Center, Inc., The Removal of antibodies from blood-derived compositions while retaining coagulation factors
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
AU6653094A (en) 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
CN1064552C (zh) 1993-02-09 2001-04-18 奥克塔法马有限公司 失活无脂质被膜病毒的方法
SE9301582D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Purification of plasma proteins
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
DE4342132C1 (de) 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
US5486293A (en) 1994-03-21 1996-01-23 Hemasure, Inc. Removal of small exogenous molecules from biological fluids
US5514781A (en) 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
US5627080A (en) 1994-07-29 1997-05-06 Beckman Instruments, Inc. Detergent-facilitated immunoassay for the rapid and quantitative assay of pharmacological agents
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
AU5136496A (en) 1995-03-10 1996-10-02 Hemasure, Inc. Inactivation of pathogens in blood and/or blood products using formaldehyde
US5985275A (en) 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US6034073A (en) 1995-04-24 2000-03-07 Novavax, Inc. Solvent detergent emulsions having antiviral activity
FI952196A0 (fi) 1995-05-08 1995-05-08 Suomen Punainen Risti Veripalv Framstaellning av immunoglobulin
US6136865A (en) 1995-05-20 2000-10-24 Octapharma Ag Method for reduction of the infectiousness of potentially infectious material
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
DE19528221C2 (de) 1995-08-01 1998-10-22 Blutspendedienst Der Drk Lande Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma
DE19544297A1 (de) 1995-11-28 1997-06-05 Behringwerke Ag Verfahren zur Entfernung von aromatischen Verbindungen aus produkthaltigen Lösungen
ES2099678B1 (es) 1995-11-03 1998-02-16 Grifols Grupo Sa Procedimiento para la inactivacion de virus en proteinas.
US5952009A (en) 1996-03-20 1999-09-14 New York Blood Center Methods for preventing the transmission of or treating patients infected with herpesvirus
US5700679A (en) 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
DE19633684A1 (de) 1996-08-12 1998-02-19 Dirk Dipl Ing Vollenbroich Verfahren zur Inaktivierung von lipidumhüllten Viren
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
EP1364944A1 (en) 1997-01-06 2003-11-26 Cerus Corporation Frangible Compounds for Pathogen Inactivation
AT405939B (de) 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
JP2001524820A (ja) 1997-04-10 2001-12-04 ライフ テクノロジーズ，インコーポレイテッド Ｒｎａ単離試薬および方法
KR20010013377A (ko) 1997-06-04 2001-02-26 데이비드 엠 모이어 마일드한 잔류성 항균 조성물
ES2286852T3 (es) 1997-08-04 2007-12-01 Advanced Life Science Institute, Inc. Metodos para detectar o analizar virus.
US6162904A (en) 1997-12-24 2000-12-19 Alpha Therapeutic Corporation Manufacturing method for intraveneously administrable immune globulin and resultant product
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
AU764138B2 (en) 1999-02-05 2003-08-14 Merck Sharp & Dohme Corp. Human papilloma virus vaccine formulations
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
WO2000061613A2 (en) 1999-04-09 2000-10-19 The Johns Hopkins University Channel forming toxins as antiviral agents
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US7087399B1 (en) 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
US7273567B1 (en) 1999-11-24 2007-09-25 Microactive Corp. Energy-activated compositions for controlled sustained release of a gas
US6441144B1 (en) 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US7279318B1 (en) 1999-06-09 2007-10-09 Hybrid Systems Limited Modification of biological elements
CA2375560A1 (en) 1999-06-15 2000-12-21 Alpha Therapeutic Corporation Manufacturing method for intravenous immune globulin and resultant product
WO2000078141A1 (en) 1999-06-23 2000-12-28 The Dial Corporation Antibacterial compositions
AU777059B2 (en) 1999-06-23 2004-09-30 Dial Corporation, The Antibacterial compositions
SE9902388D0 (sv) 1999-06-23 1999-06-23 Pharmacia & Upjohn Ab Method for purification of proteins
US6861397B2 (en) 1999-06-23 2005-03-01 The Dial Corporation Compositions having enhanced deposition of a topically active compound on a surface
AU7097400A (en) 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6517849B1 (en) 1999-10-19 2003-02-11 The Procter & Gamble Company Tissue products containing antiviral agents which are mild to the skin
US20050232868A1 (en) 1999-10-19 2005-10-20 The Procter & Gamble Company Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
JP3884652B2 (ja) 1999-12-14 2007-02-21 サーモ エレクトロン コーポレイション−ポイント オブ ケア エンド ラピッド ダイアグノスティックス ポリペプチドおよび抗原の安定化希釈液
MXPA02006540A (es) 1999-12-30 2002-12-09 Kimberly Clark Co Articulo absorbente anitmicrobial y metodos para hacer y usar el mismo.
US6893462B2 (en) 2000-01-11 2005-05-17 Regeneration Technologies, Inc. Soft and calcified tissue implants
AU2001234509A1 (en) 2000-01-20 2001-07-31 The Procter And Gamble Company Antimicrobial compositions
US20020172656A1 (en) 2000-01-20 2002-11-21 Biedermann Kimberly Ann Cleansing compositions
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
ES2319864T3 (es) 2000-04-28 2009-05-14 St. Jude Children's Research Hospital Sistema de transfeccion de adn para la generacion de virus infecciosos de arn de cadena negativa.
IL136552A (en) 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
AUPQ846900A0 (en) 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US20020018792A1 (en) 2000-06-30 2002-02-14 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care anti-sebum compositions containing 3,4,4-trichlorocarbanilide
JP2002085057A (ja) 2000-09-12 2002-03-26 Yoshiaki Nagaura ウィルスを不活化する方法
AU2001292917A1 (en) 2000-09-20 2002-04-02 Regeneration Technologies, Inc. Method of preparing and processing transplant tissue
CZ2003930A3 (cs) 2000-10-02 2003-08-13 Glaxosmithkline Biologicals S. A. Vakcinační prostředek obsahující štěpený virus s obalem
WO2002048176A1 (en) 2000-12-14 2002-06-20 Bayer Corporation Method of preparing alpha-1 proteinase inhibitor
EP2281573A3 (en) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
CA2438960A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
CN1230526C (zh) 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
IL157304A0 (en) 2001-03-16 2004-02-19 Oncolytics Biotech Inc Method of extracting virus from cell culture
US6803041B2 (en) 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
US6635679B2 (en) 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
JP2006512401A (ja) 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
US7033500B2 (en) 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
FR2827610B1 (fr) * 2001-07-17 2005-09-02 Commissariat Energie Atomique Composition de degraissage utilisable pour le degraissage et/ou la decontamination de surfaces solides
CN1208091C (zh) 2001-08-30 2005-06-29 成都夸常科技有限公司 用固定化溶剂或固定化溶剂－去污剂灭活病毒的方法
US20060110407A1 (en) 2001-12-05 2006-05-25 Shelley Stopera Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
US20030133829A1 (en) 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
GB0201039D0 (en) 2002-01-17 2002-03-06 Incenta Ltd Assay
AR038153A1 (es) 2002-01-18 2004-12-29 Schering Ag Formulaciones estabilizadas de adenovirus
US20040142450A1 (en) 2002-05-10 2004-07-22 Seo Sang Heui Lung epithelial cell line for propagating viruses
ATE360683T1 (de) 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
AR040819A1 (es) 2002-08-08 2005-04-20 Alza Corp Dispositivo de administracion transdermica de vacuna que tiene microproyecciones revestidas
CN1684994A (zh) 2002-08-09 2005-10-19 通用汽车公司 凝胶涂料组合物
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
CA2500661A1 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
SE0203551D0 (sv) 2002-12-02 2002-12-02 Biovitrum Ab Prothrombin purification
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
CA2525953C (en) 2003-05-28 2023-10-10 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
AU2004273779B2 (en) 2003-06-04 2009-10-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
US7763452B2 (en) 2003-06-25 2010-07-27 Bn Immunotherapeutics, Inc. Purification of HER-2 variants
EP2090586A1 (en) 2003-06-25 2009-08-19 BN ImmunoTherapeutics, Inc. Purification of her-2 variants
US7371395B2 (en) 2003-07-24 2008-05-13 Merial Limited Vaccine formulations
EP1651163B1 (en) 2003-08-01 2015-03-04 Biocon Limited Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same
BRPI0412835A (pt) 2003-08-12 2006-09-26 Octapharma Ag processo para preparação de uma solução de alfa-1-antitripsina
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
CA2544185C (en) 2003-10-28 2010-09-28 Advanced Life Science Institute, Inc. Method of detecting hepatitis c virus
WO2005049077A2 (en) 2003-11-17 2005-06-02 Regents Of The University Of Minnesota Avian vaccine effective against infectious bursal disease virus
JP4874806B2 (ja) 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
CN1901935A (zh) 2003-12-30 2007-01-24 惠氏公司 具有改进耐受性的免疫原组合物中的疏水性蛋白调配物
WO2005070454A2 (en) 2004-01-27 2005-08-04 Bharat Biotech International Limited A novel process of hepatitis a vaccine preparation
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
US8613934B2 (en) 2004-03-22 2013-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellular and viral inactivation
WO2009131606A2 (en) 2008-02-01 2009-10-29 Belanger Julie M Viral inactivation using crosslinkers and detergents
US20050271711A1 (en) 2004-04-26 2005-12-08 The Procter & Gamble Company Therapeutic antimicrobial compositions and methods
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
RU2411959C2 (ru) 2004-06-29 2011-02-20 Релайанс Лайф Сайенсиз Пвт Лтд Способ получения безопасных в вирусном отношении биологических текучих сред
JP4742042B2 (ja) 2004-06-30 2011-08-10 テルモ株式会社 ウィルス不活化ヘモグロビンおよびその製造方法
ATE489965T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
US20090004222A1 (en) 2004-11-03 2009-01-01 O'hagan Derek Influenza Vaccination
AU2005305347A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
AU2005229674B2 (en) 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
WO2006062897A2 (en) 2004-12-09 2006-06-15 The Dial Corporation Compositions having a high antiviral and antibacterial efficacy
EP1830638A2 (en) 2004-12-09 2007-09-12 The Dial Corporation Compositions having a high antiviral and antibacterial efficacy
EP1685852A1 (en) 2005-02-01 2006-08-02 Fondation pour la Recherche Diagnostique Set of disposable bags for viral inactivation of biological fluids
ES2569409T3 (es) 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
AR054020A1 (es) 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
WO2007014244A2 (en) 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1951200A2 (en) 2005-08-09 2008-08-06 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
WO2007022718A1 (fr) 2005-08-25 2007-03-01 Chunde Liu Alcools alkylaryle, leurs derives et leur procede de preparation
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
AU2006310338A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adminstration routes for priming/boosting with influenza vaccines
JP5005700B2 (ja) 2005-11-04 2012-08-22 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アルミニウムアジュバントに即座に吸着されるインフルエンザワクチン
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
SI1951299T1 (sl) 2005-11-04 2012-04-30 Novartis Vaccines & Diagnostic Cepiva proti influenci, ki vkljuäśujejo kombinacije adjuvantov iz delcev in imunopotenciatorjev
NZ568212A (en) 2005-11-04 2012-03-30 Novartis Vaccines & Diagnostic Changing Th1/Th2 balance in split influenza vaccines with adjuvants
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
US20070128693A1 (en) 2005-12-06 2007-06-07 Advantek Serum Laboratories Limited3/F Method for the inactivation and removal of dengue virus from biological samples
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
DK1969007T3 (da) 2005-12-20 2013-11-25 Bristol Myers Squibb Co Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
US8252339B2 (en) 2006-04-11 2012-08-28 Massachusetts Institute Of Technology Medical treatment applications of swellable and deformable microspheres
US7794755B2 (en) 2006-04-11 2010-09-14 E.I. Du Pont De Nemours And Company Process for preparation of swellable and deformable microspheres
KR101352165B1 (ko) * 2006-05-19 2014-01-15 바이로블럭 에스.에이. 외피 바이러스를 불활성화시키는 조성물
WO2007144772A2 (en) 2006-06-15 2007-12-21 Novartis Ag Adjuvant-sparing multi-dose influenza vaccination regimen
US20080003575A1 (en) 2006-06-28 2008-01-03 Sigma-Aldrich Co. Methods and composition for RNA extraction
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
WO2008073161A2 (en) 2006-08-14 2008-06-19 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US20090081193A1 (en) 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
CN101501696A (zh) 2006-08-14 2009-08-05 麻省理工学院 聚糖数据挖掘系统
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
CN101563077A (zh) 2006-10-10 2009-10-21 迈克尔·林奇 灭活病毒的方法
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
JP2010512748A (ja) 2006-12-15 2010-04-30 シェーリング−プラウ・リミテッド インフルエンザウイルスを培養物中で複製するための方法
WO2008096093A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
GB0702416D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702385D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
JP4829828B2 (ja) 2007-03-28 2011-12-07 シスメックス株式会社 血液凝固測定用試薬及び組織因子安定化方法
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
CA2685830C (en) 2007-05-24 2012-12-18 Abbott Laboratories Immunoassays exhibiting reduced cross-reactivity with hydrophobic drug analyte metabolites
WO2008154633A2 (en) 2007-06-12 2008-12-18 Rhodia Inc. Detergent composition with hydrophilizing soil-release agent and methods for using same
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
EP2192917B1 (en) 2007-08-28 2014-01-29 Baxter International Inc. Method for producing viral vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
EP2238146A4 (en) 2008-01-03 2012-03-21 Massachusetts Inst Technology HEMAGGLUTININE POLYPEPTIDES AND REAGENTS AND METHODS RELATED THEREWITH
WO2009089119A2 (en) 2008-01-03 2009-07-16 Massachusetts Institute Of Technology Decoy influenza therapies
EP2077118A1 (en) 2008-01-07 2009-07-08 Gwo Rei Biomedical Technology Corp. Clottable concentrate of platelet growth factors and preparation method thereof
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
US20110009520A1 (en) 2008-03-20 2011-01-13 Figuly Garret D Dimensionally stable, shaped articles comprised of dried, aggregated, water-swellable hydrogel microspheres and method of making same
EP2278997B1 (en) 2008-04-21 2016-08-10 Nanobio Corporation Nanoemulsion influenza vaccine
EP2274320A1 (en) 2008-04-25 2011-01-19 ID Biomedical Corporation of Quebec Methods for preparing immunogenic compositions
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
EP2300497B1 (en) 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
EP2321336A1 (en) 2008-07-18 2011-05-18 Talecris Biotherapeutics, Inc. Method of preparing alpha-1 proteinase inhibitor
CN102223876A (zh) 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
CN102317789B (zh) 2008-10-31 2014-08-27 生物梅里埃公司 利用质谱法分离、表征和/或鉴定微生物的方法
US10167494B2 (en) 2008-10-31 2019-01-01 Biomerieux, Inc. Method for detection, characterization and/or identification of microorganisms in a sealed container
US10059975B2 (en) 2008-10-31 2018-08-28 Biomerieux, Inc. Methods for the isolation and identification of microorganisms
KR20110095277A (ko) 2008-10-31 2011-08-24 바이오메리욱스, 인코포레이티드. 라만 분광법을 이용하여 미생물을 분리, 특성규명, 및/또는 동정하는 방법
US8647835B2 (en) 2008-10-31 2014-02-11 BIO MéRIEUX, INC. Methods for separation, characterization and/or identification of microorganisms using spectroscopy
BRPI0919895B1 (pt) 2008-10-31 2019-08-13 Bio Merieux Inc método para identificação de um microorganismo desconhecido a partir de uma amostra de teste
CA2741961A1 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
JP5730211B2 (ja) 2008-11-20 2015-06-03 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． ウイルスのアルギニン不活化
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
EA201171032A1 (ru) 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
US8883995B2 (en) 2009-03-06 2014-11-11 Icahn School Of Medicine At Mount Sinai Live attenuated influenza virus vaccines comprising microRNA response elements
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
EA201171370A1 (ru) 2009-05-08 2012-05-30 Новартис Аг Универсальные способы определения вирусов гриппа
US8609392B2 (en) 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
EA021009B1 (ru) 2009-05-21 2015-03-31 Новартис Аг ОБРАТНАЯ ГЕНЕТИКА С ИСПОЛЬЗОВАНИЕМ НЕЭНДОГЕННЫХ ПРОМОТОРОВ pol I
TWI445714B (zh) 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
NZ596671A (en) 2009-05-29 2013-06-28 Novartis Ag Assays for influenza virus hemagglutinins
CA2765511C (en) 2009-06-16 2015-05-12 The Regents Of The University Of Michigan Nanoemulsion vaccines
WO2011003100A2 (en) 2009-07-02 2011-01-06 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
AT516600B1 (de) 2009-07-23 2016-07-15 Baxter Int Herstellung von faktor h (fh) und fh-derivaten aus plasma
CN104862335A (zh) 2009-07-31 2015-08-26 诺华股份有限公司 反向遗传系统
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
UA107940C2 (en) 2009-09-10 2015-03-10 Merial Ltd The vaccine composition that includes the saponin-containing adjuvant
CA2778332A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
WO2011072097A1 (en) 2009-12-09 2011-06-16 Glaxosmithkline Llc Coating for latex articles
IT1397061B1 (it) 2009-12-28 2012-12-28 Kedrion Spa Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale.
CN101732711A (zh) 2009-12-31 2010-06-16 中国人民解放军军事医学科学院微生物流行病研究所 一种喷鼻免疫流感五价或多价灭活疫苗的制备及其应用
EP2536425B1 (en) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2011121020A1 (en) 2010-03-30 2011-10-06 Octapharma Ag A process for purifying vitamin k dependent proteins such as coagulation factor ix
KR101951446B1 (ko) 2010-03-30 2019-02-22 옥타파마 아게 성장 인자 단백질을 정제하는 방법
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
ES2402144T3 (es) 2010-05-25 2013-04-29 Gwowei Technology Co., Ltd. Lisado plaquetario inactivado que contiene factores de crecimiento empobrecido en PDGF y VEGF y su procedimiento de preparación
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
ES2717177T3 (es) 2010-07-23 2019-06-19 Baxalta GmbH Fabricación de proteínas inhibidoras inter-alfa (IaIp) a partir de plasma
AU2011300402B2 (en) 2010-09-07 2015-01-22 Novartis Ag Generic assays for detection of mammalian reovirus
JP2013541528A (ja) 2010-09-21 2013-11-14 マサチューセッツ インスティテュート オブ テクノロジー ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置
JP6029586B2 (ja) 2010-10-04 2016-11-24 マサチューセッツ インスティテュート オブ テクノロジー 血球凝集素ポリペプチド、ならびにそれに関連する試薬および方法
WO2012055951A2 (en) 2010-10-27 2012-05-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
MX2013004975A (es) 2010-11-02 2014-01-17 Opko Pharmaceuticals Llc Vacunas novedosas contra el virus pandémico de la influenza a/h1n1.
AP2013006835A0 (en) 2010-11-02 2013-04-30 Zepeda Lopez Hector Manuel Novel vaccines against the A/H1N1 pandemic flu virus
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
CN102464974B (zh) 2010-11-17 2013-08-07 中国石油化工股份有限公司 可大幅度提高原油采收率的组合物及其制备方法
CN103370072B (zh) 2010-12-15 2016-02-03 巴克斯特国际公司 使用改进的溶剂-清洁剂方法进行病毒灭活
IL210162A0 (en) 2010-12-21 2011-03-31 Omrix Biopharmaceuticals Viral inactivated platelet extract, use and preparation thereof
WO2012118789A2 (en) 2011-02-28 2012-09-07 The Ohio State University Enhanced removal of viruses from fresh produce
KR20120098202A (ko) 2011-02-28 2012-09-05 (주)차바이오앤디오스텍 자하거 추출물 및 자하거 추출물 제조 방법
LT2681553T (lt) 2011-03-04 2017-11-10 Baxalta GmbH Polisorbato nustatymo būdas
US9017950B2 (en) 2011-03-18 2015-04-28 Luminescent MD, LLC Method for enhancing enzyme assays
KR20140022845A (ko) 2011-03-25 2014-02-25 제넨테크, 인크. 신규 단백질 정제 방법
EP2714076A1 (en) 2011-05-26 2014-04-09 GlaxoSmithKline Biologicals S.A. Inactivated dengue virus vaccine
EP2726097A4 (en) 2011-07-01 2015-03-11 Univ California HERPES VIRUS VACCINE AND METHOD OF USE
EP2729169A1 (en) 2011-07-06 2014-05-14 Nanobio Corporation Human respiratory syncytial virus vaccine
CN103813845B (zh) 2011-07-22 2016-08-17 生物梅里埃有限公司 从培养物离析微生物的方法和试剂盒
US9534037B2 (en) 2011-08-02 2017-01-03 Baxalta GmbH Systems and methods to increase protein yield from recombinant manufacturing processes
CN104093421A (zh) 2011-09-09 2014-10-08 纳诺碧欧公司 纳米乳液呼吸道合胞病毒(rsv)亚单位疫苗
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
EP2768528A1 (en) 2011-10-20 2014-08-27 Novartis AG Adjuvanted influenza b virus vaccines for pediatric priming
WO2013135274A1 (en) 2012-03-13 2013-09-19 Intercell Ag Aluminium compounds for use in therapeutics and vaccines
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
CN103608453B (zh) 2012-03-02 2018-07-24 思齐乐 流感病毒重配
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
US20130315955A1 (en) 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
CN102614508B (zh) 2012-04-28 2013-10-30 长春生物制品研究所有限责任公司 一种人用流感病毒裂解疫苗的病毒裂解灭活方法
WO2014004103A1 (en) 2012-06-29 2014-01-03 Emd Millipore Corporation Methods for inactivating viruses during a protein purification process
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
US9353165B2 (en) 2012-07-25 2016-05-31 Grifols, S.A. Purification of cell culture derived alpha1 protease inhibitor
US10188732B2 (en) 2012-08-06 2019-01-29 Biogen Ma Inc. Methods and compositions for inactivating enveloped viruses
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
AU2013337346A1 (en) 2012-11-05 2015-05-14 Medimmune, Llc Method of isolating Synagis in the absence of benzonase
KR20150110494A (ko) 2012-12-03 2015-10-02 노파르티스 아게 재배열 인플루엔자 a 바이러스
CN102943000A (zh) 2012-12-17 2013-02-27 江南大学 一种活性氧增彩洗衣液
CN109045294A (zh) 2013-01-10 2018-12-21 思齐乐 流感病毒免疫原性组合物及其应用
MX2015009330A (es) 2013-01-23 2016-04-15 Novartis Ag Reordenamiento del virus de influenza.
TWI641382B (zh) 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
US20140335504A1 (en) 2013-02-07 2014-11-13 Massachusetts Institute Of Technology Human adaptation of h5 influenza
US9393252B2 (en) 2013-03-12 2016-07-19 Ecolab Usa Inc. Aromatic carboxylic acids in combination with aromatic hydroxyamides for inactivating non-enveloped viruses
SG11201507454XA (en) 2013-03-13 2015-10-29 Novartis Ag Influenza b virus reassortment
WO2014167582A2 (en) 2013-03-31 2014-10-16 Ella Foundation Vaccine composition for prophylaxis in ruminants
WO2015126462A1 (en) 2014-02-19 2015-08-27 Materia, Inc. Preparation of surfactants via cross-metathesis
US9758445B2 (en) * 2013-04-09 2017-09-12 Materia, Inc. Preparation of surfactants via cross-metathesis
WO2014179464A1 (en) 2013-04-30 2014-11-06 Massachusetts Institute Of Technology Human adaptation of h3 influenza
FR3005265B3 (fr) 2013-05-06 2017-01-27 Novartis Ag Reassortiment du virus de la grippe
SG11201509265SA (en) 2013-05-10 2015-12-30 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
CN103392691B (zh) 2013-08-14 2015-09-23 北京瑞健高科生物科技有限公司 一种生物组织处理、灭菌及保存的容器和方法
WO2015031689A1 (en) 2013-08-30 2015-03-05 Personalis, Inc. Methods and systems for genomic analysis
HUE057005T2 (hu) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
WO2015047105A1 (en) 2013-09-30 2015-04-02 Resman As Chemical compounds
CA2926089C (en) 2013-10-24 2022-08-30 Medimmune, Llc Stable, aqueous antibody formulations
JP6373376B2 (ja) 2013-11-15 2018-08-15 ノバルティス アーゲー 残留細胞培養不純物の除去
WO2015073633A1 (en) 2013-11-15 2015-05-21 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents
EP3076993A1 (en) 2013-12-05 2016-10-12 Janssen Vaccines & Prevention B.V. Process for preparing influenza vaccines
US10357559B2 (en) 2013-12-27 2019-07-23 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
CN110859957B (zh) 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
CN106456813B (zh) 2014-04-15 2020-06-30 勃林格殷格翰国际公司 在制造生物制品期间连续灭活病毒的方法、装置和系统
PE20170471A1 (es) 2014-06-13 2017-05-14 Santa Maria Biotherapeutics Inc Polipeptidos receptores formulados y metodos relacionados
AU2015305690A1 (en) 2014-08-18 2017-03-02 Sanofi Pasteur Inc. Alkylated influenza vaccines
CN104211943B (zh) 2014-09-17 2016-08-24 南京卡邦科技有限公司 一种制备分离单分散聚乙二醇的方法
CN104324370B (zh) 2014-09-30 2019-12-20 普莱柯生物工程股份有限公司 疫苗组合物及其制备方法和应用
PL3209767T3 (pl) 2014-10-21 2021-01-11 Gennova Biopharmaceuticals Ltd. Nowy sposób oczyszczania do izolacji i komercyjnej produkcji zrekombinowanego tnk-tpa (tenekteplazy)
HRP20210737T1 (hr) 2014-12-01 2021-06-11 Ferring B.V. Primjena selektivnog inhibitora il-6-trans-signalizacije
DK3227325T3 (da) 2014-12-01 2024-07-08 Ferring Bv Sammensætninger med selektive hæmmere af il-6-trans-signalering
CA2970158A1 (en) 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
WO2016100926A1 (en) 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza
CN104548084A (zh) 2014-12-30 2015-04-29 吕宏亮 一种广谱粘膜免疫防控猪繁殖与呼吸综合症的疫苗组合物及其应用
AU2016228806B2 (en) 2015-03-12 2020-10-22 Medimmune, Llc Method of purifying albumin-fusion proteins
MX2017012389A (es) 2015-03-27 2018-09-19 Cadila Healthcare Ltd Vacuna del virus de la parotiditis recombinante jeryl lynn2.
JP6651300B2 (ja) 2015-04-23 2020-02-19 山本化成株式会社 フタロシアニン化合物、これを含有する近赤外線カットフィルタ
AU2016270979B2 (en) 2015-06-02 2020-11-12 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
US10927151B2 (en) 2015-06-09 2021-02-23 Sanofi Pasteur Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
WO2017004153A1 (en) 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
WO2017053374A1 (en) 2015-09-21 2017-03-30 Oregon Health & Science University Design and characterization of influenza vaccines
US20200237898A1 (en) 2015-09-21 2020-07-30 Oregon Health & Science University Vaccines intelligently produced by epitope recombination (viper) for influenza
CN109311965B (zh) 2016-03-11 2023-07-18 勃林格殷格翰国际公司 在制造蛋白质期间连续灭活病毒的方法
CN106187714A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚及其制备方法
CN106117264A (zh) 2016-07-19 2016-11-16 南京林业大学 烷基苯甲醇聚氧乙烯醚磷酸铵及其制备方法
CN106187833A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚硫酸铵及其制备方法
CN106187828A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚琥珀酸二钠盐及其制备方法
CN106187713A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚羟丙基烯丙基醚及衍生物及其制备方法
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN109400449B (zh) 2018-09-29 2022-06-10 中国日用化学研究院有限公司 一种制备烷基苯基醇聚氧乙烯醚的方法

Also Published As

Publication number Publication date
CN111511800A (zh) 2020-08-07
JP7432506B2 (ja) 2024-02-16
EP3704178A1 (en) 2020-09-09
AU2018357917B2 (en) 2024-08-01
EP3704178B1 (en) 2024-07-24
JP2021501163A (ja) 2021-01-14
ES2991988T3 (es) 2024-12-05
BR112020008414A2 (pt) 2020-11-17
WO2019086463A1 (en) 2019-05-09
RU2020117357A (ru) 2021-12-01
SG11202003793WA (en) 2020-05-28
RU2020117357A3 (es) 2022-03-30
KR102651043B1 (ko) 2024-03-22
US20210032567A1 (en) 2021-02-04
US12258540B2 (en) 2025-03-25
AU2018357917A1 (en) 2020-05-07
CA3080656A1 (en) 2019-05-09
KR20200071127A (ko) 2020-06-18
MX2020004151A (es) 2020-08-13
CN111511800B (zh) 2023-11-28

Similar Documents

Publication Publication Date Title
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
MA39803A (fr) Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
MX2015011529A (es) Reordenamiento del virus de infuenza b.
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
PH12017500858A1 (en) Mocrocyclic peptides useful as immunomodulators
EA201890736A1 (ru) Модуляторы корового белка вируса гепатита b
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
EA201790630A1 (ru) Способы получения рибозидов
MX2015016755A (es) Reagrupamiento del virus de influenza.
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
MX2018000880A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
MX380902B (es) Métodos para la inactivación viral usando detergentes ecológico.
UY40872A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
PH12016500492A1 (en) Pyridazinone compounds and uses thereof
MX377357B (es) Compuestos para dispositivos ópticamente activos.
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
MX393092B (es) Bis-compuestos para dispositivos opticamente activos.
CO2020006181A2 (es) Detergentes compatibles con el medio ambiente para la inactivación de virus envueltos en lípidos
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
CO2020001426A2 (es) Método para incubar líquidos e inactivar virus
BR112017006680A2 (pt) variantes de vírus influenza a
MX2015009330A (es) Reordenamiento del virus de influenza.
CL2017000151A1 (es) Derivados de piridona